新药周观点：ELCC2026国产ADC优异数据披露-20260322

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [7] Core Insights - The report highlights the upcoming European Lung Cancer Conference (ELCC 2026) scheduled for March 25-28, 2026, in Copenhagen, Denmark, where significant data disclosures are expected from domestic companies [3][24] - Notable clinical trial results have been reported, including the final overall survival (OS) data for科伦博泰's TROP2 ADC sac-TMT in EGFR-mutant non-small cell lung cancer and 百利天恒's EGFR×HER3 dual antibody ADC iza-bren in extensive-stage small cell lung cancer [24][29] Summary by Sections Weekly New Drug Market Review - From March 16 to March 22, 2026, the top five gainers in the new drug sector were 三生国健 (+23.14%), 旺山旺水 (+12.90%), 派格生物医药 (+10.29%), 海思科 (+10.12%), and 泽璟制药 (+9.53%). The top five losers were 迈博药业 (-25.71%), 开拓药业 (-24.81%), 轩竹生物 (-14.00%), 药捷安康 (-10.50%), and 亚虹医药 (-10.30%) [19][21] Weekly Focus on Recommended Stocks - The report suggests focusing on stocks with potential catalysts, including: 1. Companies with overseas data catalysts: 贝达药业, 映恩生物, 和黄医药 2. Companies with MNC certification and high certainty for future overseas volume: 三生制药, 联邦制药, 科伦博泰 3. Potential heavyweights for overseas licensing by MNC: 复宏汉霖, 石药集团, 益方生物 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat reduction and muscle gain, autoimmune CAR-T/dual antibodies, gene therapy [2][23] Weekly New Drug Industry Analysis - The report emphasizes the significance of the ELCC 2026 conference, where key data from clinical trials will be presented, showcasing the efficacy of new treatments in lung cancer [3][24] Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were reported this week, but three new drug or new indication applications were accepted [31] Weekly New Drug Clinical Application Approval & Acceptance Status - A total of 63 new drug clinical applications were approved, and 27 new drug clinical applications were accepted this week [33]